The company said, “MaxCyte (MXCT) increases 2024 revenue guidance for core business revenue and affirms SPL Program-related revenue guidance. MaxCyte now expects full year 2024 core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY. MaxCyte continues to expect to end 2024 with approximately $185 million in cash, cash equivalents and investments.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MXCT:
- MaxCyte Streamlines Workforce and Boosts Revenue Outlook
- MaxCyte Expands Stock Capital Amid Cell Therapy Growth
- MaxCyte’s Voting Rights Shift with BlackRock Acquisition
- MaxCyte Sees Shift in BlackRock’s Shareholding
- MaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead